Education
About Us
Working with TipRanks
Follow Us
Sprint Bioscience AB (DE:5JA1)
FRANKFURT:5JA1
Total Valuation
Sprint Bioscience AB has a market cap or net worth of €4.29M. The enterprise value is €175.12M.
Market Cap€4.29M
Enterprise Value€175.12M
Share Statistics
Sprint Bioscience AB has 105,515,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,515,540
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sprint Bioscience AB’s return on equity (ROE) is -1.97 and return on invested capital (ROIC) is -212.12%.
Return on Equity (ROE)-1.97
Return on Assets (ROA)-0.43
Return on Invested Capital (ROIC)-212.12%
Return on Capital Employed (ROCE)-2.12
Revenue Per Employee1.73M
Profits Per Employee-517.58K
Employee Count38
Asset Turnover1.56
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sprint Bioscience AB is -5.96. Sprint Bioscience AB’s PEG ratio is >-0.01.
PE Ratio-5.96
PS Ratio0.00
PB Ratio0.83
Price to Fair Value11.75
Price to FCF-0.39
Price to Operating Cash Flow-0.39
PEG Ratio>-0.01
Income Statement
In the last 12 months, Sprint Bioscience AB had revenue of 65.64M and earned -18.28M in profits. Earnings per share was -0.26.
Revenue65.64M
Gross Profit37.30M
Operating Income-19.67M
Pretax Income-18.28M
Net Income-18.28M
EBITDA-17.32M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -23.36M and capital expenditures -1.30M, giving a free cash flow of -24.65M billion.
Operating Cash Flow-23.36M
Free Cash Flow-24.65M
Free Cash Flow per Share-0.23
Dividends & Yields
Sprint Bioscience AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.46
52-Week Price Change-81.82%
50-Day Moving Average0.03
200-Day Moving Average0.09
Relative Strength Index (RSI)42.48
Average Volume (3m)0.00
Important Dates
Sprint Bioscience AB upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateMay 27, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Sprint Bioscience AB as a current ratio of 1.14, with Debt / Equity ratio of 0.00%
Current Ratio1.14
Quick Ratio1.14
Debt to Market Cap0.00
Net Debt to EBITDA1.45
Interest Coverage Ratio-491.70
Taxes
In the past 12 months, Sprint Bioscience AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Sprint Bioscience AB EV to EBITDA ratio is -4.84, with an EV/FCF ratio of -3.40.
EV to Sales1.28
EV to EBITDA-4.84
EV to Free Cash Flow-3.40
EV to Operating Cash Flow-3.59
Balance Sheet
Sprint Bioscience AB has €25.06M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€25.06M billion.
Cash & Marketable Securities€25.06M
Total Debtkr0.00
Net Cash-€25.06M
Net Cash Per Share-€0.24
Tangible Book Value Per Share€0.13
Margins
Gross margin is -73384.34%, with operating margin of -29.96%, and net profit margin of -27.84%.
Gross Margin-73384.34%
Operating Margin-29.96%
Pretax Margin-27.84%
Net Profit Margin-27.84%
EBITDA Margin-26.38%
EBIT Margin-27.78%
Analyst Forecast
The average price target for Sprint Bioscience AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―